Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-04-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于公司副总经理、核心技术人员离职及新增核心技术人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a company's vice general manager and core technical personnel, as well as the addition of new core technical personnel. It details personnel changes, their roles, and the impact on the company. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content focuses on management and board-level personnel changes, specifically senior management and core technical staff. This fits the category of Board/Management Information (MANG). The document length is 3563 characters, which is consistent with a detailed announcement but not a full report. Therefore, the classification is MANG with high confidence.
2024-04-19 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司副总经理、核心技术人员离职及新增核心技术人员的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the departure and addition of key technical personnel and a deputy general manager at Maiwei (Shanghai) Biotechnology Co., Ltd. It includes specific personnel changes, their roles, and the impact on the company’s operations and R&D capabilities. The document is a formal verification opinion by the sponsor institution, not a financial report, earnings release, or regulatory announcement. It does not contain financial data or earnings information, nor is it a voting result or capital change notice. It is a regulatory compliance-related report about management and key personnel changes, which fits best under Board/Management Information (MANG). The document length is 3510 characters, which is not extremely short, and it contains substantive content about management changes rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-19 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司2023年度持续督导年度跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导年度跟踪报告" which translates to "2023 Annual Continuous Supervision Follow-up Report" by the sponsoring securities company for a listed biotech company. It details the continuous supervision activities conducted by the sponsor (Haitong Securities) over the year 2023, including compliance with regulatory requirements, internal controls, governance, financial status, and risk disclosures. The document references regulatory approvals, ongoing monitoring, and compliance with listing rules. It is not a full annual report or financial statement but a regulatory continuous supervision report by the sponsor. This type of document fits the category of Audit Report / Information (AR) as it relates to audit, regulatory oversight, and continuous supervision reports rather than full annual reports or earnings releases. The document length and detailed content confirm it is a substantive report, not just an announcement or certification.
2024-04-09 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司2023年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (on-site inspection report) by the sponsoring institution (海通证券股份有限公司) regarding the continuous supervision of a listed company for the year 2023. It details the scope and findings of the on-site inspection, covering governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, and operational status. The document is a formal report issued by the sponsor as part of regulatory continuous supervision obligations, not a full annual report or audit report. It is not an announcement of voting results, nor a financial statement or earnings release. The content aligns with a regulatory or audit-related report but is specifically a continuous supervision on-site inspection report by the sponsor, which fits best under Audit Report / Information (AR) as it is a standalone audit/supervisory report related to regulatory compliance and internal controls, not a full annual report or interim report. The document length is 3464 characters, which is substantive and contains detailed findings, not a brief announcement or certification letter, so it is not RNS or RPA. Therefore, the best classification is AR with high confidence.
2024-04-09 Chinese
迈威生物关于续聘公司2024年度审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of the company's audit firm for the 2024 fiscal year. It details the background and qualifications of the audit firm, the audit team, the audit fees, and the approval process by the board and supervisory committee. It does not contain any actual financial statements or audit reports but rather informs shareholders and the public about the intention to continue with the audit firm and the procedural steps involved. The document is relatively short (3103 characters) and serves as a formal announcement rather than the audit report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-04-08 Chinese
迈威生物2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled '2023年度会计师事务所履职情况评估报告' which translates to '2023 Annual Evaluation Report on the Performance of the Accounting Firm'. It discusses the appointment and evaluation of the audit firm Ernst & Young Hua Ming for the 2023 fiscal year, including their qualifications, audit procedures, and the company's assessment of their performance. The document does not contain actual financial statements or detailed financial data but rather an evaluation of the audit firm's work and compliance with auditing standards. It is not an Annual Report (10-K) or Audit Report (AR) itself but an assessment related to the audit firm’s performance. Given the content and length (1530 characters), it fits best under Audit Report / Information (AR) as it relates to audit activities and evaluation of the auditor's performance, rather than a full annual report or a simple announcement. Therefore, the classification is AR with high confidence.
2024-04-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.